

ASX Announcement

5 March 2020

All figures are provided in US\$

Business Update – Year to Date Sales Contracts Executed

US\$9.1m Clinical Trials Sales Contracts Executed Since 1 January 2020

US\$36.0m Clinical Trials Sales Contracts Executed FY20 year to date

Cogstate (ASX:CGS) has today announced that it has executed \$9.1 million of clinical trials sales contracts since 1 January 2020.

Following a record half year result of \$26.9 million of clinical trials sales contracts executed for the 6 months to 31 December 2019, the additional contracts executed since 1 January 2020 take the total value of clinical trials sales contracts executed since 1 July 2019 to \$36.0 million.

For context, a history of Clinical Trials sales contracts executed, per quarter, since 1 July 2016 is provided:

	Sep Quarter \$m	Dec Quarter \$m	1 st Half \$m	Mar Quarter \$m	Jun Quarter \$m	2 nd Half \$m	Financial Year
FY17	\$17.3	\$5.7	\$23.0	\$3.6	\$3.0	\$6.6	\$29.6
FY18	\$7.5	\$14.1	\$21.6	\$8.3	\$6.2*	\$14.5	\$36.1
FY19	\$5.4	\$4.6	\$10.0	\$3.8	\$4.1	\$7.9	\$17.9
FY20 (to date)	\$7.7	\$19.2	\$26.9	\$9.1**	n/a	n/a	n/a

*Excludes \$6.4m of study cancellations that were recognised at 30 June 2018.

** Not a full quarter – includes the period 1 January 2020 – 4 March 2020

This announcement was authorised for release by a sub-committee of the Board of Directors of Cogstate Ltd.

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For nearly 20 years, Cogstate has proudly supporting the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, Cogstate has recently entered into an exclusive licensing agreement with pharmaceutical company, Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. For more information, please visit www.cogstate.com.

For further information contact:

Brad O'Connor
Cogstate Chief Executive Officer
boconnor@cogstate.com